Context: Adrenal tumors in noncancer patients are common. Objective: Evaluate performance of 18F-fluorodeoxyglucose positron emission tomography computed tomography (18F-FDG-PET/CT) in distinguishing between benign and malignant adrenal tumors. Design: Retrospective chart review 2010-2019. Setting: Academic institution. Patients: One hundred and seventeen noncancer patients, defined as having no history of cancer or with cancer in remission for ≥5 years, completed 18F-FDG-PET/CT to evaluate adrenal masses, with pathologic diagnoses or imaging follow-up (≥12 months). Intervention: 18F-FDG-PET/CT of 117 indeterminate adrenal masses. Main Outcome Measures: Receiver operator characteristic curve of the ratios of adrenal lesion standardized uptake value (SUV)max to liver SUVmean and of adrenal lesion SUVmax to aortic arch blood pool SUVmean were constructed. Results: Seventy benign and 47 malignant masses (35 adrenocortical carcinomas [ACCs], 12 adrenal metastases) were identified. Malignant masses had higher median liver SUV and blood pool SUV ratios than benign masses (6.2 and 7.4 vs 1.4 and 2.0, P
CITATION STYLE
He, X., Caoili, E. M., Avram, A. M., Miller, B. S., & Else, T. (2021). 18F-FDG-PET/CT Evaluation of Indeterminate Adrenal Masses in Noncancer Patients. Journal of Clinical Endocrinology and Metabolism, 106(5), 1448–1459. https://doi.org/10.1210/clinem/dgab005
Mendeley helps you to discover research relevant for your work.